# The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy

> **NCT02905916** · PHASE4 · UNKNOWN · sponsor: **Peking University** · enrollment: 217 (estimated)

## Conditions studied

- Mammary Cancer
- Lymphoma
- Bone Tumour
- Gynecological Tumors

## Interventions

- **DRUG:** PEG-rhG-CSF

## Key facts

- **NCT ID:** NCT02905916
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06
- **Primary completion:** 2018-06
- **Final completion:** —
- **Target enrollment:** 217 (ESTIMATED)
- **Last updated:** 2016-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02905916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02905916, "The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT02905916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*